HAEMONETICS CORP/MASS (HAE)
US4050241003 - Common Stock
Taking everything into account, HAE scores 6 out of 10 in our fundamental rating. HAE was compared to 192 industry peers in the Health Care Equipment & Supplies industry. While HAE has a great profitability rating, there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: HAE is growing strongly while it also seems undervalued. These ratings could make HAE a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
HAE had positive earnings in the past year.
HAE had a positive operating cash flow in the past year.
Each year in the past 5 years HAE has been profitable.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
HAE has a better Return On Assets (5.75%) than 84.38% of its industry peers.
HAE's Return On Equity of 13.41% is amongst the best of the industry. HAE outperforms 89.06% of its industry peers.
HAE has a better Return On Invested Capital (7.70%) than 86.98% of its industry peers.
HAE had an Average Return On Invested Capital over the past 3 years of 5.44%. This is below the industry average of 8.50%.
The last Return On Invested Capital (7.70%) for HAE is above the 3 year average (5.44%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.75% | ||
| ROE | 13.41% | ||
| ROIC | 7.7% |
ROA(3y)4.22%
ROA(5y)4.6%
ROE(3y)10.25%
ROE(5y)10.41%
ROIC(3y)5.44%
ROIC(5y)7.59%
1.3 Margins
With an excellent Profit Margin value of 9.96%, HAE belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
In the last couple of years the Profit Margin of HAE has grown nicely.
HAE has a Operating Margin of 15.69%. This is amongst the best in the industry. HAE outperforms 87.50% of its industry peers.
In the last couple of years the Operating Margin of HAE has grown nicely.
HAE has a Gross Margin of 53.48%. This is comparable to the rest of the industry: HAE outperforms 47.40% of its industry peers.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.69% | ||
| PM (TTM) | 9.96% | ||
| GM | 53.48% |
OM growth 3Y-6.47%
OM growth 5Y5.4%
PM growth 3Y8.46%
PM growth 5Y14.38%
GM growth 3Y2.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HAE is destroying value.
The number of shares outstanding for HAE has been reduced compared to 1 year ago.
The number of shares outstanding for HAE has been reduced compared to 5 years ago.
HAE has a better debt/assets ratio than last year.
2.2 Solvency
HAE has an Altman-Z score of 3.60. This indicates that HAE is financially healthy and has little risk of bankruptcy at the moment.
HAE's Altman-Z score of 3.60 is fine compared to the rest of the industry. HAE outperforms 70.31% of its industry peers.
The Debt to FCF ratio of HAE is 6.76, which is on the high side as it means it would take HAE, 6.76 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.76, HAE is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
A Debt/Equity ratio of 0.91 indicates that HAE is somewhat dependend on debt financing.
The Debt to Equity ratio of HAE (0.91) is worse than 75.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | 6.76 | ||
| Altman-Z | 3.6 |
ROIC/WACC0.82
WACC9.36%
2.3 Liquidity
HAE has a Current Ratio of 2.92. This indicates that HAE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HAE (2.92) is comparable to the rest of the industry.
A Quick Ratio of 1.76 indicates that HAE should not have too much problems paying its short term obligations.
HAE has a Quick ratio of 1.76. This is in the lower half of the industry: HAE underperforms 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.30% over the past year.
HAE shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.25% yearly.
Looking at the last year, HAE shows a quite strong growth in Revenue. The Revenue has grown by 12.47% in the last year.
HAE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.27% yearly.
EPS 1Y (TTM)32.3%
EPS 3Y-2.9%
EPS 5Y10.25%
EPS growth Q2Q22.35%
Revenue 1Y (TTM)12.47%
Revenue growth 3Y5.74%
Revenue growth 5Y5.27%
Revenue growth Q2Q10.14%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.77% on average per year.
HAE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.94% yearly.
EPS Next Y31.97%
EPS Next 2Y21.21%
EPS Next 3Y17.66%
EPS Next 5Y18.77%
Revenue Next Year12.18%
Revenue Next 2Y8.95%
Revenue Next 3Y7.73%
Revenue Next 5Y8.94%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 23.98, the valuation of HAE can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 83.33% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of HAE to the average of the S&P500 Index (24.67), we can say HAE is valued inline with the index average.
A Price/Forward Earnings ratio of 20.74 indicates a rather expensive valuation of HAE.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 85.42% of the companies listed in the same industry.
HAE's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.02.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.98 | ||
| Fwd PE | 20.74 |
4.2 Price Multiples
HAE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HAE is cheaper than 82.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 83.33% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.38 | ||
| EV/EBITDA | 18.27 |
4.3 Compensation for Growth
HAE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HAE may justify a higher PE ratio.
HAE's earnings are expected to grow with 17.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.75
PEG (5Y)2.34
EPS Next 2Y21.21%
EPS Next 3Y17.66%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HAEMONETICS CORP/MASS
NYSE:HAE (5/1/2024, 9:57:08 AM)
92.305
+0.36 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.69B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.98 | ||
| Fwd PE | 20.74 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.75
PEG (5Y)2.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.75% | ||
| ROE | 13.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 15.69% | ||
| PM (TTM) | 9.96% | ||
| GM | 53.48% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)32.3%
EPS 3Y-2.9%
EPS 5Y
EPS growth Q2Q
EPS Next Y31.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.47%
Revenue growth 3Y5.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y